Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat WST09 VTP for Recurrent Prostate Cancer
NCT00305929Phase 2Completed
- Sponsor
- Steba Biotech
- Start
- Mar 2006
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of padoporfin in prostate cancer (PCa), sponsored by Steba Biotech. Primary endpoint: Prostate biopsy status at 12 months. Started Mar 2006; status: completed.
02
Drugs
padoporfin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00305929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00305929.